| Name | Valirx |
|---|---|
| Epic | VAL |
| Isin | GB00BLH13C52 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 1.64p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £2.17 | Debt ratio | n/a |
| Shares in issue | 132.35 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -191.03 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -3.06 | 52-week high / low | 1.23p / 11.25p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Valirx |
|---|---|
| Address | Stonebridge House, Chelmsford Road, Hatfield Heath, United Kingdom, CM22 7BD |
| Telephone | |
| Website | http://www.valirx.com |
| Director | Position |
|---|---|
| Dr Suzanne Dilly | CEO |
| Mr Gerald Desler | CFO |
| Mr Martin Lampshire | Non-Executive Director |
| Mr Adrian de Courcey | Non-Executive Director |
| Dr Kevin Cox | Non-Executive Chairman |
| Mr Martin Gouldstone | Non-Executive Director & Chairman |
| Assets £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Reporting date | 31/12/22 | 31/12/21 | 31/12/20 |
| Intangible asssets and goodwill | 2.51 | 2.71 | 2.93 |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 2.51 | 2.72 | 2.95 |
| Inventory / work in progress | n/a | n/a | n/a |
| Trade and other receivables | 0.33 | 0.21 | 0.07 |
| Cash and equivalents | 1.14 | 0.59 | 1.85 |
| Other current assets and asset held for resale | n/a | n/a | 0.07 |
| Total of all assets | 3.98 | 3.52 | 4.94 |
| Liabilities £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Short term liabilities | 0.13 | 0.07 | 0.12 |
| Long term liabilities | 0.02 | 0.04 | 0.06 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 0.15 | 0.11 | 0.18 |
| Net assets £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Net assets | 3.83 | 3.41 | 4.76 |
| Equity £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Share capital | 9.7 | 9.67 | 9.67 |
| Minority interests | -0.22 | -0.18 | -0.16 |
| Retained earnings | -34.64 | -32.29 | -30.92 |
| Share premium account | 26.77 | 24.49 | 24.38 |
| Total equity | 3.83 | 3.41 | 4.76 |
| Income £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -2.59 | -1.68 | -1.65 |
| Pre-tax profit | -2.6 | -1.68 | -1.54 |